Rep. Jake Auchincloss (D-MA) criticizes FDA’s new voucher program that offers select drugmakers sharply shortened review timelines, arguing the program undermines scientific standards and the agency’s credibility.
Acting CDER director Tracy Beth Hoeg looks to hire the petitioner behind a request the Center is considering to add new Warnings to commonly prescribed antidepressants, a move many believe is a conflict of interest.
Rep. Jake Auchincloss (D-MA) criticizes FDA’s new voucher program that offers select drugmakers sharply shortened review timelines, arguing the program undermines scientific standards and the agency’s credibility.
Acting CDER director Tracy Beth Hoeg looks to hire the petitioner behind a request the Center is considering to add new Warnings to commonly prescribed antidepressants, a move many believe is a conflict of interest.
FDA places a partial clinical hold on a mid-stage U.S. trial of PepGen Inc.’s experimental therapy for myotonic dystrophy Type 1.
FDA denies an Age Reversal Unity petition asking the agency to establish a framework and issue guidance for expedited clinical trials for aging-related therapeutics.
